joining To in our first early the continues well multiple you, a today. to Bob. remain our thank demand variant to continues for extremely therapy steady. Omicron quarter, everyone, impact in us begin, the while business perform you for had Welcome, and Thank slight indication
strong will Importantly, recent commercial, growth lead operating highlighted that fronts beyond. our and positive by our in growth XXXX our driving on are we quarters throughout expect achievements and current to further clinical, regulatory BrainsWay for reimbursement trends that latest
prospects first, provide While summary accomplishments detail and I in our I overview greater financial key will future most a of first shortly, results. our review an brief of our will quarter recent
consecutive revenue quarter XX% $X first for The increase of represented in quarter demand growth. anxious depression, year-over-year driven of the OCD depression, TMS an first Deep Our therapies, seventh reflecting business. emerging over by both quarter million XXXX and and balance the with our was the
helmets number quarter. fact, the our key for shipped I XXXX our priorities OCD In I’d depression recent helmets the the equal and prism we a like to HX for on key last HX within outlined nearly call. of discuss of accomplishments during
this its BrainsWay smaller the LifeSciences, a XX sales as more some Most revenue first as of and experience allow that look leading leader Sales. of we market. and visibility pillars Covidien, stimulation becoming To commercial BrainsWay’s We device market years sales veteran such new growth, Hirt way continued are that these is of the demonstrates leveraging this the our him appointed deep recently, us the achieve brain growth assembled leading as growing President expertise Teleflex trend. believe with further are best-in-class The leading is Eric non-invasive steps we well companies to in for forward we to will therapy. leader at strong Integra a to companies. taking team. we’ve as Vice we Eric TMS market than in Deep increase device his medical medical and
regions two broadening territory out build U.S. last focused said to Collectively, As three this going for are our sales our call, on year to focus from managers. professionals territory is sales XX these our regions with XX base. sales in with customer infrastructure managers our I by
clinical Our development territory laser and highly continue to sales field practice in These past on expanding professionals overall knowledgeable focused customer an cultivating managers are support to have will the complemented customer and engineers. skilled and teams superior supported on and customers. our success, to provide by consultants be delivering achieving base of mandate our
pillar Another strategic awareness. aspect this increasing market of is
visible Our XXXX. for am been XX% in to as our of search compared website the quarter engine organic need. make I the therapy TMS optimization enhanced recently for has pleased first all report continues grow, website first overhauled that to Deep XXXX, to increasing in traffic of to more quarter
chat website first engagements nearly quarter. robot individuals H-Coil, X,XXX the with logged Our in
chats to led patients. approximately customers online discussions of these for and prospective further Importantly, XX%
We Additionally, feature treatment. to of health website will and month awareness hashtag greater the sales engagement don’t that channels media moment. month use with were medical to another initiatives patients XX of our following describing now these to of with our any of May tool. the miss share alternative booked campaign is more enjoy of experiences, believe engagement including mental on of awareness certain we in meetings details initiatives a This number exciting lead reach management this also ultimately Deep activities potential is awareness have seeking our health to centric breakthrough patient We’ll an they online Moreover, traditional nearly patient patient utilizing social goal clinics further TMS Collectively, increased their are technology. and mental will next mental an able planned, call. health.
look and XXXX coming related whenever possible, you Where in and initiatives prospective in-person interactions a the with marketing for that have leverage we with critical continue to We number existing months. of exciting sharing other we forward to customers. awareness planned
of two in as seven the In over Psychiatric and site, fact, American Meeting, Association clinical Deep will I Europe Australia. bit the OCD, pillar. on medical it aspect including TMS now strategic other participate across another first and a turn up picks of quite psychiatric the next our treatment our meetings will the conferences to we progress health Annual the on and for months mental U.S., TMS society,
this device and company own TMS remains placebo-controlled on have is device. achieved based hard pivotal its BrainsWay reminder, data to TMS for condition clearance clearance to FDA first on conducted received only the this treat a the to As
XX first add-on for quarter, number we increasing the During treatments OCD shipped XXX. helmets that total to
benefits to capability. are our reimbursement this nearly in includes broader install Deep treatment total We in that XX% customers belief pleased progress OCD treatment as the view of for and strong a our our base OCD the this TMS emerging now area. within of We of context testament
published number focus excited an reimbursement. just and reimbursement area the to on anxious our device I’m two Palmetto the in our important eligible approximately OCD X for to order OCD Deep reimbursement better customers failed new facilitate of to reimbursement enhances of are research our of end, this with we’re cost broader program LCD to reminder on significant further the excited their publish to effectiveness of coverage. In support XX the reimbursement order of terms in a for and indicative medications. Deep achieved it collective and indication. program in BrainsWay. OCD adoption leading to-date brand continue of now The also is have ongoing traction As This impacted developments recent the customer we coverage lives since we upgraded of and The this with the additional available in compelling reduced progress, BrainsWay in durability support are four treat positively Palmetto and materials OCD access increase seeing likelihood in medications depression May to we launched adoption training key highlighting is requirement using million. year of failed in peer a two TMS to earlier that TMS of depression customers TMS both those Further total of OCD. to in support, journals data determination, also to expansion and customer use new Deep the and resources OCD. accelerate reviewed To this
lead in is second evidence. the strategic on Moving superior plan science a and pillar to through
focus efforts of publications industry continue major presentations all in data real depression indications, our advance a including We at and and key our and depression conferences. with on to collection anxious addiction OCD smoking and world
intend to indications. certain neurological addiction in feasibility studies and new we psychiatric, several addition, In key initiate
our for us. reflects appointment our drivers has fourth the newly a Dr. and help corporate are of new growing the third commitment business XX overseeing long-term created President opportunities business. strategy than experience internationally and and more development, in appointed Dr. this in this the and Joe market we is development pillars Seidel U.S. enhancing and Strategy. for responsible positions development management critical on and and end, He order in platform Vice and years position device capitalizing of program The To Development are research both both corporate medical These to global Corporate of of strategy, continue to Seidel our continue business to Dr. in opportunities for initiatives. pursuing Seidel’s strategic development. BrainsWay pursuing industry our activities.
Levy, to will the function. on growth business. role, plan In strategic focus with Operating and for long-term was General and In North Vice of organization July for enhancing been Senior support be since for prior with on entire our his leading U.S. we business Hadar focus a BrainsWay customer Chief implementing a who operations role, international responsible and promoted this previously President week, Hadar’s addition, developing XXXX In the this America Manager Officer. Hadar has
doubled. like look year role. update this TMS to number addiction. international forward now Hadar’s period, would deep smoking three broader for his including to markets commercialization for BrainsWay’s our provide U.S. plan an impact in and total that, a our assistants I new brief We During With on business, revenues nearly on
controlled in a this recently, a our We phase build our our early and of to medical we’re models further develop the offering strategy first kind business We and release. addressable about in strategy. ideal a patient a develop reminder, a for a rollout in customers, reimbursement in phase, progress year population the first the product order its market and release data cultivate addiction previously date. which this with limited was ago. device the more to As year, pleased release, full to We refined market first pursued was post-marketing launched concluded optimized transitioned this market message, space to completed
and currently We testimonials support marketing sales developing are efforts. our patient to
to compelling randomized such publish TMS, indications, indication. Deep smokers. Data and study intervention. other TMS the in we deepest To which these leveraged post-marketing target, – which further data, reaches to in were and placebo along Deep active treating HX with presented therapeutic are recently, to data does us used conduct as efforts successfully insula blood our also treat its nature, region, TMS with TMS that efforts. continue flow highlighting XXXX, we as the secure in schizophrenic in along journal published serve As also that will coil confirmed we to for key regards, controlled efforts that of Most this smoking leading patients scientific Deep in intend imaging collection data our this our commercialization presented in efficacy smoking we reimbursement BrainsWay exist a our will which research who well efforts The results not the addiction. Deep we facilitate alters yet addiction, and know, be allowing in believe for you a
the Investor provided He to of Dr. virtual the depression. Hospital clinical in event Professor This Brigham include recent of we School. attended Women’s of Psychiatry and March label Medical a well KOL anxious and Relations, our to of at depression market – a the terrific expansion importance Siddiqi, depression. Shan on anxious at deep neuropsychiatrist a overview focused Turning of Assistant featured event Harvard hosted
high healthcare worth and quarter. shows road non-deal virtual at We institutional investment we also conferences XXXX. net conducted first And several in throughout focused present the multiple will
who commitment like health always, partners the as thank mental crisis first results. day, every I’ll excellence team to elevating his health Scott? quarter for transform each the that, our their XXXX boldly review providers in and advancing entire Finally, and valued and call delivering to on our as to our now BrainsWay I of well the as neuroscience and would for financial lives. improve pass With Scott to mission battle of
